Chargement en cours...

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

PURPOSE: (188)Re-HEDP is indicated for the treatment of pain in patients with painful osteoblastic bone metastases, including hormone-refractory prostate cancer patients. Efficacy may be improved by adding chemotherapy to the treatment regimen as a radiation sensitizer. The combination of (188)Re-HE...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lam, Marnix G. E. H., Bosma, Tjitske B., van Rijk, Peter P., Zonnenberg, Bernard A.
Format: Artigo
Langue:Inglês
Publié: Springer-Verlag 2009
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2724641/
https://ncbi.nlm.nih.gov/pubmed/19319526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-009-1119-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!